| 5.01 Data as of 12:39pm ET |  +0.04 / +0.80%Today’s Change | 1.12 Today|||52-Week Range 7.59 | +207.83% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $248.6M |
Company Description
NanoViricides, Inc. is a development stage company, which is engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It engages in the discovery, development, and commercialization of anti-viral therapeutics primarily in the United States. The company has six drug development programs: Oral FluCide against all Influenzas, A Piggy-back version of Flucide for hospitalized patients, nanoviricide eye drops against adenoviral EKC and herpes keratitis, HIVCide-I against HIV/AIDS, HerpeCide-I skin cream formulation for herpes cold sores and genital warts, and DengueCide, is designed to attack all types of dengue viruses effective in the Severe Dengue Disease syndromes including Dengue Hemorrhagic Fever (DHS) and Dengue Shock Syndrome. The company was founded by Anil R. Diwan on July 25, 2000 and is headquartered in West Haven, CT.
Employees
Shareholders
| Individual stakeholders | 5.63% |
| Other institutional | 0.25% |
| Mutual fund holders | 0.02% |
Top Executives
| Anil R. Diwan | Chairman, President & Secretary |
| Eugene Seymour | Chief Executive Officer & Director |
| Meeta R. Vyas | Chief Financial Officer |
| Randall W. Barton | Chief Scientific Officer |
| Jayant Tatake | Vice President-Research & Development |
.
